Today's RGBP PR makes my blood boil. No date of call, no time frame for extra safety trial, no info on how this will impact dCellVax IND. [But the reading between the lines is that because dCellVax is also a cell based drug, more safety trials in a GLP approved clinic will be necessary - so after a couple years of dealing with the FDA, Koos and Ichim and Suhy have finally found out that they didn't do the trials in a proper lab. Wow, after being president of Medistem and submitting and resubmitting modified INDs, we now find out that at some point Koos found out their saftey data isn't good enough and how they should do it. Hey, 2 years of back and forth and 4 months after submitting their recent IND in May, we find out. So much for the to the moon news. Hopefully they realize this affects dCellVax before too long.]
Nothing substantial in PR to help us know the future other than verifying what we should have been told weeks or months ago. Or even worse, they just talked to the FDA about what they need to do 5 months after resubmitting their modified IND on May 6th.
It takes 4 months to get an empty PR with no substantial info on what, how long or when their first major drug could be resubmitted to FDA for clinical trial approval.
I just sold 90% of my BMSN holdings at a huge loss this morning as I'm sick of this. Maybe buy back at .001
Holding on to the free divvy shares in case this eventually gets some kind of act together.
